The average price target for Viking Therapeutics shares stands at $92.72, implying a potential upside of approximately 181% from current trading levels. However, this ambitious valuation is almost entirely contingent on the clinical progress of one specific drug candidate.
A Competitive Landscape in Flux
The competitive environment for weight-loss medications shifted notably yesterday. Novo Nordisk reached a settlement with Hims & Hers Health in a patent dispute while simultaneously forging a partnership to distribute Ozempic and Wegovy through third-party platforms. Furthermore, Novo Nordisk announced plans to significantly reduce the list prices of its GLP-1 drugs starting in 2027. This move signals intensifying price pressure within the anti-obesity pharmaceutical market.
For Viking Therapeutics, this means the market its lead candidate aims to enter is being actively reshaped by established players. Lower competitor pricing and new distribution channels raise the bar for product differentiation. Viking is banking on its dual agonist approach and its combination of injectable and oral formulations to stand out.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
The Core Driver: VK2735
At the heart of Viking’s valuation is VK2735, an investigational treatment for chronic obesity. Ongoing Phase 3 trials for the injectable version are scheduled for completion in 2027. The company also plans to advance the oral formulation into Phase 3 studies later this year, specifically in the third quarter of 2026. Market experts emphasize that the robustness of the clinical trial data will ultimately determine whether the company’s current market valuation is justified.
The next concrete test for the stock’s valuation will come with the planned initiation of Phase 3 trials for the oral formulation in Q3 2026. Until then, the equity’s performance remains closely tied to the perceived prospects of this single asset.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from March 10 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 10.
Viking Therapeutics: Buy or sell? Read more here...
